Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

17.96 -16.03 (-47.15%)
Streaming Delayed Price Updated: 10:32 AM EST, Dec 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,221,335
Open 18.51
Bid (Size) 17.96 (2,000)
Ask (Size) 17.97 (100)
Prev. Close 33.99
Today's Range 16.70 - 18.86
52wk Range 21.73 - 71.71
Shares Outstanding 41,833,315
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'? ↗
Shares crashed Tuesday on what one analyst called an "overreaction" to the company's prostate cancer treatment update. 
Via Investor's Business Daily
News headline image
These stocks are moving in today's pre-market session ↗
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill

Performance

YTD
-66.3%
-66.3%
1 Month
-34.4%
-34.4%
3 Month
-21.4%
-21.4%
6 Month
-28.2%
-28.2%
1 Year
-55.3%
-55.3%

More News

Read More
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire
News headline image
Navigating 10 Analyst Ratings For Janux Therapeutics ↗
Via Benzinga
News headline image
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux (JANX) R&D Soars Revenue Misses ↗
Via The Motley Fool
News headline image
Why Janux Therapeutics Crushed the Market Today ↗
Via The Motley Fool
News headline image
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
From Janux Therapeutics
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
Via Benzinga
News headline image
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
The Top 5 Mid Cap Stocks Of 2024 ↗
Via Talk Markets
Topics Stocks / Equities
News headline image
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio? ↗
Via Benzinga
News headline image
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Janux Therapeutics Announces Proposed Public Offering
From Janux Therapeutics
Via Business Wire

Frequently Asked Questions

Is Janux Therapeutics, Inc. - Common Stock publicly traded?
Yes, Janux Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Janux Therapeutics, Inc. - Common Stock trade on?
Janux Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Janux Therapeutics, Inc. - Common Stock?
The ticker symbol for Janux Therapeutics, Inc. - Common Stock is JANX on the Nasdaq Stock Market
What is the current price of Janux Therapeutics, Inc. - Common Stock?
The current price of Janux Therapeutics, Inc. - Common Stock is 17.96
When was Janux Therapeutics, Inc. - Common Stock last traded?
The last trade of Janux Therapeutics, Inc. - Common Stock was at 12/02/25 10:32 AM ET
What is the market capitalization of Janux Therapeutics, Inc. - Common Stock?
The market capitalization of Janux Therapeutics, Inc. - Common Stock is 751.51M
How many shares of Janux Therapeutics, Inc. - Common Stock are outstanding?
Janux Therapeutics, Inc. - Common Stock has 752M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.